July 7, 2023

To Listing Department, **NATIONAL STOCK EXCHANGE OF INDIA LIMITED** Exchange Plaza, Bandra Kurla Complex, Bandra (E), **MUMBAI -400 051** **Company Code No. AUROPHARMA**	To The Corporate Relations Department **BSE LIMITED** Phiroz Jeejeebhoy Towers, 25th floor, Dalal Street, **MUMBAI -400 001** **Company Code No. 524804**

Dear Sir/ Madam,

Sub: Disclosure under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015

This is to inform that CuraTeQ Biologics Private Limited ("**CuraTeQ**"), a wholly owned subsidiary of the Company, has entered into an exclusive license agreement with the USA based BioFactura Inc, USA to commercialize BFI-751, a proposed biosimilar to Stelara (Ustekinumab). Ustekinumab is a recombinant monoclonal antibody which is used for treating Crohn's disease, ulcerative colitis, plaque psoriasis and psoriatic arthritis.

The disclosure pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 and Part A of Schedule III of the aforesaid regulations, is attached as 'Annexure A'.

We also enclose a copy of the Press Release that is being issued in connection with the above subject.

Please take the above information on record.

Yours faithfully,
For **AUROBINDO PHARMA LIMITED**

ADIREDDY BADDIGAM
Digitally signed by ADIREDDY BADDIGAM
Date: 2023.07.07 17:02:52 +05'30'

B. Adi Reddy
Company Secretary

Encl: a/a

Annexure A

Disclosure under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015

a) name(s) of parties with whom the agreement is entered;	BioFactura Inc, USA
b) purpose of entering into the agreement	➢ To commercialize Ustekinumab biosimilar on an exclusive license right basis in all major regulated markets including US, EU, UK, Canada, ANZ and certain other semi-regulated and emerging markets worldwide. ➢ BioFactura plans to begin a global Phase 3 trial of the product as a next milestone. CuraTeQ intends to file this product in India and Emerging Markets as early as in 2024. The regulated markets filing is expected to begin in 2026. ➢ The global sales reported for Stelara (Ustekinumab) is around USD 9.72 Bn for the year 2022
c) size of agreement	BioFactura will receive license fees, a total of not exceeding USD 33.5 million spread across different milestones leading to commercialization in regulated markets.
d) shareholding, if any, in the entity with whom the agreement is executed;	Nil
e) significant terms of the agreement (in brief) special rights like right to appoint directors, first right to share subscription in case of issuance of shares, right to restrict any change in capital structure etc.;	➢ A profit-sharing arrangement has been agreed by both the parties with CuraTeQ receiving 57 - 60% of the profits depending upon the markets. ➢ CuraTeQ to have global manufacturing rights for the Ustekinumab biosimilar.
f) whether the said parties are related to promoter/promoter group/ Group companies in any manner. If yes, nature of relationship;	No
g) whether the transaction would fall within related party transactions? If yes, whether the same is done at "arm's length";	No
h) in case of issuance of shares to the parties, details of issue price, class of shares issued	Not Applicable
i) in case of loan agreements, details of lender, nature of the loan, total amount of loan granted, total amount outstanding, date of execution of the loan agreement/sanction letter, details of the security provided to the lenders for such loan;	Not Applicable

j) any other disclosures related to such agreements, viz., details of nominee on the board of directors of the listed entity, potential conflict of interest arising out of such agreements, etc;	Not Applicable
k) in case of termination or amendment of agreement, listed entity shall disclose additional details to the stock exchange(s): i. name of parties to the agreement; ii. nature of the agreement; iii. date of execution of the agreement; iv. details of amendment and impact thereof or reasons of termination and impact thereof.	Not Applicable

ADIREDDY BADDIGAM

Digitally signed by ADIREDDY BADDIGAM
Date: 2023.07.07 17:03:24 +05'30'

Press Release

Hyderabad, India, 7th July 2023

CuraTeQ obtains exclusive rights for BioFactura's Ustekinumab biosimilar

Aurobindo Pharma Limited (along with its subsidiaries together referred to as "Aurobindo") is pleased to announce that CuraTeQ Biologics Private Limited, its wholly owned subsidiary, has entered into an exclusive license agreement with the USA based BioFactura to commercialize BFI-751, a proposed biosimilar to Stelara (Ustekinumab). Ustekinumab is a recombinant monoclonal antibody that works by blocking both interleukins IL-12 and IL-23 and is used for treating Crohn's disease, ulcerative colitis, plaque psoriasis and psoriatic arthritis. The global drug sales of Ustekinumab stood at close to 10 billion in 2022 presenting a significant opportunity with a good number of indications and a wider use.

Under the terms of the agreement, CuraTeQ have been granted exclusive license rights to commercialize BFI-751 in all major regulated markets including US, EU, UK, Canada, ANZ and certain other semi-regulated and emerging markets worldwide. Additionally, CuraTeQ will have the global manufacturing rights for this product, which will be produced at CuraTeQ facilities in Hyderabad, India. BioFactura plans to begin a global Phase 3 trial of the product as the next logical milestone in development. CuraTeQ intends to file this product in India and Emerging Markets as early as in 2024 and the regulated markets filing is expected to begin in 2026.

Commenting on the deal with BioFactura, Dr. Satakarni Makkapati, CEO – Biologics, Vaccines and Peptides, Aurobindo Pharma said, "BioFactura has demonstrated bio-equivalence of BFI-751 vs US and EU registered originator product Stelara in a three-arm Phase 1 study conducted in 200 plus healthy subjects. We are excited by the prospect of this Ustekinumab biosimilar advancing to Phase 3 clinical studies in the due course of time. Ustekinumab fits into our expanding immunology products portfolio very well and we will use our presence across key markets to commercialize this product."

Commenting on the deal with BioFactura, Mr. Nithyananda Reddy, MD and Vice Chairman, Aurobindo Pharma said, "This agreement underscores our investment intentions in biosimilars business. It is our commitment to improve lives of patients suffering from these debilitating immune and inflammatory diseases by delivering them access to cost-effective and high quality biosimilars such as Ustekinumab. "

Commenting on the development, Darryl Sampey, Ph.D., President and CEO of BioFactura said, "The development of our BFI-751 biosimilar to Stelara has been an all-encompassing endeavor at BioFactura which led to the impressive clinical results of our pivotal bio-comparability trial. With CuraTeQ, we have found the optimal partner to successfully complete the journey and bring this important product to market."

Additionally, Jeffrey N Hausfeld, MD, MBA., Chairman and Chief Medical Officer of BioFactura, stated, "The purpose and regulatory framework of bringing biosimilars into the mainstream of healthcare systems worldwide should be focused on improving outcomes, quality of life, accessibility, and enhancing the patient experience, with medicines proven to be as potent, pure, safe, and effective as the branded drugs. We are proud to partner with CuraTeQ to bring BioFactura's high quality biosimilar of Ustekinumab to the global marketplace in order to fulfill these goals."

Aurobindo Pharma Limited (www.aurobindo.com), (NSE: AUROPHARMA, BSE: 524804, Reuters: ARBN.NS, Bloomberg: ARBP IN) is an integrated global pharmaceutical company headquartered in Hyderabad, India. The Company develops, manufactures, and commercializes a wide range of generic pharmaceuticals, branded specialty pharmaceuticals and active pharmaceutical ingredients globally in over 150 countries.

The company has 24 manufacturing and packaging facilities that are approved by leading regulatory agencies including USFDA, UK MHRA, EDQM, Japan PMDA, WHO, Health Canada, South Africa MCC, Brazil ANVISA. The company's robust product portfolio is spread over 7 major therapeutic/product areas encompassing CNS, Anti-Retroviral, CVS, Antibiotics, Gastroenterological, Anti-Diabetics and Anti-Allergic, supported by a strong R&D set-up.
To know more, please log on to www.aurobindo.com

For further information or queries, please contact:

Soumen Biswas | Deepti Thakur
Investor Relations | Corporate Communications
Phone: +91 40 66725401 / 66725000
Email: ir@aurobindo.com

Disclaimer:

This press release contains statements that may constitute "forward looking statements" including and without limitation, statements relating to product characteristics and uses, sales potential and target dates for product launch, implementation of strategic initiatives, and other statements relating to our future business developments and economic performance. While these forward-looking statements represent our judgment and future expectations concerning the development of our business, a number of risks, uncertainties and other factors could cause actual developments and results to differ materially from our expectations. The company undertakes no obligation to publicly revise any forward-looking statements to reflect future events or circumstances and will not be held liable for any use of this information.

ADIREDDY BADDIGAM
Digitally signed by ADIREDDY BADDIGAM
Date: 2023.07.07 17:03:42 +05'30'